Otsuka details positive Phase 3 IgAN data as it awaits FDA decision

Otsuka has shared the specifics of a late-stage win for a rare kidney disease treatment that’s on track to become its first wholly-owned product to be sold in the US. The biotech’s monoclonal antibody, called …